President and Chief Executive Officer
Anthony Johnson M.D. is the President and Chief Executive Officer of Domain Therapeutics. In this role, he is dedicated to accelerating the global development of Domain’s innovative and uniquely positioned GPCR-derived immuno-oncology programs, with the ultimate goal of combating cancer and solidifying Domain’s position as a key player in the field of GPCRs.
Tony brings over 25 years of experience to Domain, spanning academia, the biopharmaceutical industry and venture capital. His illustrious career includes roles at internationally renowned companies such as AstraZeneca, OrbiMed Advisors, Bristol Myers Squibb, and GSK, and he most recently served as President and CEO of Goldfinch Bio. Throughout his career, Tony has been instrumental in advancing multiple products in the clinic and has made significant contributions to new drug approvals. Tony holds a medical degree and research doctorate from the University of New South Wales and achieved Fellowship of the Royal Australasian College of Physicians in Sydney.